OBJECTIVE: Interpreting genome-scale genetic association data, particularly for complex diseases and phenotypes, requires extensive use of prior knowledge across a broad range of potential biological and environmental influences, spanning many scientific subdisciplines. We suggest that known or hypothesized disease risk factors, and causal mechanisms, can be represented using an ontology, a computational specification of a set of concepts and the relations between them. METHODS: We have integrated the expertise of multiple investigators in nicotine pharmacokinetics and pharmacodynamics, nicotine dependence, and clinical smoking cessation outcomes, and represented this knowledge in an ontology-based network model. Our model spans multiple scales, from molecules, genes and cellular pathways, to complex behavioral phenotypes and even environmental factors. To leverage previous and ongoing work in the field of ontology development, we adopt, expand upon and relate elements from existing ontologies whenever possible. RESULTS: We discuss several applications of our ontology: to support interdisciplinary research by graphically representing a complex scientific theory, to facilitate meta-analysis across different studies, to highlight potential interactions, and to support statistical analysis and causal modeling. We demonstrate that our ontology can focus hypothesis testing on areas supported by current theory. CONCLUSION: We describe how an ontology-based computational representation can be applied to disease risk factors and mechanisms, enabling the use of prior knowledge in large-scale genetic association studies in general. In specific, we have developed an initial Smoking Behavior Risk Ontology to support studies related to the pharmacogenetics of nicotine addiction and treatment.
OBJECTIVE: Interpreting genome-scale genetic association data, particularly for complex diseases and phenotypes, requires extensive use of prior knowledge across a broad range of potential biological and environmental influences, spanning many scientific subdisciplines. We suggest that known or hypothesized disease risk factors, and causal mechanisms, can be represented using an ontology, a computational specification of a set of concepts and the relations between them. METHODS: We have integrated the expertise of multiple investigators in nicotine pharmacokinetics and pharmacodynamics, nicotine dependence, and clinical smoking cessation outcomes, and represented this knowledge in an ontology-based network model. Our model spans multiple scales, from molecules, genes and cellular pathways, to complex behavioral phenotypes and even environmental factors. To leverage previous and ongoing work in the field of ontology development, we adopt, expand upon and relate elements from existing ontologies whenever possible. RESULTS: We discuss several applications of our ontology: to support interdisciplinary research by graphically representing a complex scientific theory, to facilitate meta-analysis across different studies, to highlight potential interactions, and to support statistical analysis and causal modeling. We demonstrate that our ontology can focus hypothesis testing on areas supported by current theory. CONCLUSION: We describe how an ontology-based computational representation can be applied to disease risk factors and mechanisms, enabling the use of prior knowledge in large-scale genetic association studies in general. In specific, we have developed an initial Smoking Behavior Risk Ontology to support studies related to the pharmacogenetics of nicotine addiction and treatment.
Authors: Dalin Li; Stephanie J London; Jinghua Liu; Wonho Lee; Xuejuan Jiang; David Van Den Berg; Andrew W Bergen; Denise Nishita; Nahid Waleh; Gary E Swan; Peggy Gallaher; Chih-Ping Chou; Jean C Shih; Jennifer B Unger; W James Gauderman; Frank Gilliland; C Anderson Johnson; David V Conti Journal: Am J Epidemiol Date: 2011-03-16 Impact factor: 4.897
Authors: Katrina G Claw; Julie A Beans; Seung-Been Lee; Jaedon P Avey; Patricia A Stapleton; Steven E Scherer; Ahmed El-Boraie; Rachel F Tyndale; Deborah A Nickerson; Denise A Dillard; Kenneth E Thummel; Renee F Robinson Journal: Nicotine Tob Res Date: 2020-05-26 Impact factor: 4.244
Authors: Jill Hardin; Yungang He; Harold S Javitz; Jennifer Wessel; Ruth E Krasnow; Elizabeth Tildesley; Hyman Hops; Gary E Swan; Andrew W Bergen Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-12 Impact factor: 4.254
Authors: Andrew W Bergen; Harold S Javitz; Ruth Krasnow; Denise Nishita; Martha Michel; David V Conti; Jinghua Liu; Won Lee; Christopher K Edlund; Sharon Hall; Pui-Yan Kwok; Neal L Benowitz; Timothy B Baker; Rachel F Tyndale; Caryn Lerman; Gary E Swan Journal: Pharmacogenet Genomics Date: 2013-02 Impact factor: 2.089
Authors: Duncan C Thomas; David V Conti; James Baurley; Frederik Nijhout; Michael Reed; Cornelia M Ulrich Journal: Hum Genomics Date: 2009-10 Impact factor: 4.639
Authors: Andrew W Bergen; Harold S Javitz; Li Su; Yungang He; David V Conti; Neal L Benowitz; Rachel F Tyndale; Caryn Lerman; Gary E Swan Journal: Nicotine Tob Res Date: 2012-12-03 Impact factor: 4.244